Fiera Capital Corp reduced its position in shares of Stryker Co. (NYSE:SYK) by 5.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,975 shares of the medical technology company’s stock after selling 949 shares during the period. Fiera Capital Corp’s holdings in Stryker were worth $3,155,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the stock. Welch Group LLC grew its holdings in Stryker by 1.5% during the first quarter. Welch Group LLC now owns 3,774 shares of the medical technology company’s stock worth $745,000 after acquiring an additional 54 shares during the period. Independence Bank of Kentucky increased its stake in Stryker by 4.9% in the 1st quarter. Independence Bank of Kentucky now owns 1,180 shares of the medical technology company’s stock worth $233,000 after purchasing an additional 55 shares in the last quarter. Benedict Financial Advisors Inc. increased its stake in Stryker by 1.1% in the 1st quarter. Benedict Financial Advisors Inc. now owns 5,235 shares of the medical technology company’s stock worth $1,034,000 after purchasing an additional 57 shares in the last quarter. Berman Capital Advisors LLC increased its stake in Stryker by 11.1% in the 1st quarter. Berman Capital Advisors LLC now owns 571 shares of the medical technology company’s stock worth $112,000 after purchasing an additional 57 shares in the last quarter. Finally, 1ST Source Bank increased its stake in Stryker by 3.5% in the 1st quarter. 1ST Source Bank now owns 1,760 shares of the medical technology company’s stock worth $348,000 after purchasing an additional 60 shares in the last quarter. 73.61% of the stock is currently owned by hedge funds and other institutional investors.
In other Stryker news, VP Bijoy Sagar sold 2,000 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $190.43, for a total transaction of $380,860.00. Following the completion of the sale, the vice president now directly owns 3,350 shares in the company, valued at approximately $637,940.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Yin C. Becker sold 15,240 shares of the firm’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $198.03, for a total value of $3,017,977.20. Following the sale, the vice president now owns 16,577 shares of the company’s stock, valued at $3,282,743.31. The disclosure for this sale can be found here. Insiders have sold a total of 82,303 shares of company stock valued at $15,947,489 over the last 90 days. Corporate insiders own 7.20% of the company’s stock.
A number of equities analysts recently weighed in on SYK shares. Barclays set a $203.00 price target on Stryker and gave the stock a “buy” rating in a research note on Friday, March 8th. BTIG Research lifted their price target on Stryker to $211.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Deutsche Bank lifted their price target on Stryker from $181.00 to $208.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Canaccord Genuity lifted their price target on Stryker from $190.00 to $195.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $209.00 price target on the stock in a research note on Thursday, April 25th. Six equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Stryker presently has a consensus rating of “Buy” and an average target price of $196.75.
Shares of NYSE SYK opened at $196.78 on Friday. Stryker Co. has a one year low of $144.75 and a one year high of $199.85. The stock has a market cap of $72.68 billion, a price-to-earnings ratio of 26.92, a price-to-earnings-growth ratio of 2.37 and a beta of 0.81. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.12 and a quick ratio of 1.30.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, April 23rd. The medical technology company reported $1.88 EPS for the quarter, topping the Zacks’ consensus estimate of $1.84 by $0.04. Stryker had a return on equity of 26.72% and a net margin of 25.38%. The firm had revenue of $3.52 billion during the quarter, compared to analyst estimates of $3.51 billion. During the same period last year, the company posted $1.68 EPS. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. Equities analysts expect that Stryker Co. will post 8.15 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, June 27th. This represents a $2.08 dividend on an annualized basis and a yield of 1.06%. Stryker’s payout ratio is presently 28.45%.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
See Also: What are the FAANG Stocks?
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.